

Managing common infections NICE guideline
Clostridioides difficile infection: antimicrobial prescribing
(Meeting 3)
Minutes

Date: 19/12/19

Location: NICE Office, Manchester

Committee members present:

Tessa Lewis – Chair (TL)	Present for items 1 - 5
Yarni Finney (YF)	Present for items 1 - 5
Alastair Hay (AH)	Present for items 1 - 5
Ian Hill-Smith (IH)	Present for items 1 - 5
Susan Hopkins (SH)	Present for items part of 1 - 5
Philip Howard (PH)	Present for items 1 - 5
Amelia Joseph (AJ)	Present for items part of 4 - 5
Marisa Lanzman (ML)	Present for items 1 - 5
Paddy McMaster (PM)	Present for items 1 - 5
John Morris (JM)	Present for items 1 - 5
Mitul Patel (MP)	Present for items 1 - 5
Carole Pitkeathley (CP)	Present for items 1 - 5

Expert witness:

Mark Wilcox	Present for items 1 - 5
-------------	-------------------------

In attendance (NICE):

Sara Buckner (SB)	Present for items 1 - 5
Alex Curwen (AC)	Present for items 1 - 5
Rupert Franklin (RF)	Present for items 1 - 5
Ruth Garnett (RG)	Present for items 1 - 5
James Jagroo (JJ)	Present for items 1 - 5
Albany Meikle (AM)	Present for items 1 - 5
Greg Moran (GM)	Present for items 1 - part of 4
Louise Picton (LP)	Present for items 1 - 5
Joshua Pink (JP)	Present for items 1 - 3
Ian Pye (IP)	Present for items 1 - 5
Jonathan Underhill (JU)	Present for items 1 - 5

Apologies:

Stephanie Dancer, Avril Tucker, Caroline Ward

1. Welcome, introductions and apologies

The chair welcomed the committee members and attendees to clostridioides difficile infection: antimicrobial prescribing meeting 3 of the public health advisory committee D (managing common infections committee). The committee members and attendees introduced themselves.

The chair informed the committee that apologies had been received as noted above.

The chair outlined the objectives of the meeting, which included:

- Network meta-analysis and P scores in Beinortas and Health Economics modelling for Clostridioides difficile infection
- Discussion of evidence, draft recommendations for guidance on the prevention of Clostridioides difficile infection: antimicrobial prescribing

2. Declaration of interests

The chair asked the committee to declare any new or relevant interests. There were no relevant additional interests declared.

3. Network meta-analysis and P scores in Beinortas and Health Economics modelling for Clostridioides difficile infection

SB presented notes on the studies considered at the last clostridioides difficile infection (CDI) committee meeting on treatment.

SB introduced JP to clarify some of the network meta-analysis results from the last meeting and P scores.

11:09 SH joined the meeting and declared her interests, which included papers on CDI. However, none of these were included in the analysis and pre-date 2016. The chair and a senior member of the NICE Development team (NDT) noted that the interests declared did not prevent SH from participating in the meeting.

JP explained that he is gathering information to help with economic analysis and will be acting as the bridge between NICE and York Health Economics Consortium (YHEC). He asked the committee questions around recurrence and time duration.

JP invited any further questions or information and summarised the next steps.

4. Discussion of evidence, draft recommendations for guidance on the prevention of Clostridioides difficile infection: antimicrobial prescribing

JJ presented the evidence on antibiotics for the prevention of CDI.

The committee discussed the evidence presented.

GM presented the evidence on monoclonal antibodies for prevention of recurrence of CDI.

The committee discussed the evidence presented.

GM delivered the evidence on probiotics for the prevention of CDI in children and young people, which concluded the presentation of evidence.

The committee discussed the evidence presented.

TL thanked MW for his contributions.

14:30 MW left the meeting.

14:50 CP left the meeting.

RG displayed the guideline and talked through the amends that had been made to the treatment of CDI content since the last meeting.

The committee agreed draft recommendations for prevention of CDI.

5. Any other business

No additional items were raised. The meeting closed at 16:00.